Citius Oncology, Inc. (CTOR) News
Follow Citius Oncology, Inc. (CTOR) news in one place: company catalysts, earnings, analyst actions and wider market developments. Review 2 public stories across 2 publication days to understand how the story developed. Public news appears after a 15-minute delay; LiveCast subscribers can follow new headlines and hear important updates without this additional delay.
M
Citius Oncology Reports 120% Growth in LYMPHIR Shipments
Preliminary, unaudited fiscal fourth-quarter 2026 sales totaled 792 LYMPHIR units to U.S. wholesalers, up 120% from the prior quarter. Prescribing centers ordered 950 vials, and 54 institutions had ordered LYMPHIR as of
EQUITY | Oct 26, 2026, 08:16 PM UTC
M
12 Health Care Stocks Move
Gainers Universe Pharmaceuticals (NASDAQ: UPC ) stock moved upwards by 168.2% to $7.94 during Friday's after-market session. The market value of their outstanding shares is at $1.8 million. Tvardi Therapeutics (NASDAQ: T
EQUITY | Jun 26, 2026, 11:20 PM UTC